Yongchang Tang
Overview
Explore the profile of Yongchang Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yuan F, Tang Y, Liang H, Cao M, Ren Y, Li Y, et al.
Genomics
. 2025 Jan;
117(2):110999.
PMID: 39863187
Introduction: Resistance to lenvatinib limits the effectiveness of the targeted treatments for HCC. However, the exact mechanism behind this resistance remains elusive. Current research suggests that circular RNA (circRNA) is...
2.
Tang Y, Wang H, Zhang J, Yang C, Xu F, Song Y, et al.
Sci Rep
. 2025 Jan;
15(1):2477.
PMID: 39833282
The crosstalk between cancers and the immune microenvironment plays a critical role in malignant progression. FMS-like tyrosine kinase 3 (FLT3) is a frequently mutated gene in acute myeloid leukemia (AML)....
3.
Tang Y, Xu L, Zhang G, Li K, Shi A, Shu L, et al.
Eur J Surg Oncol
. 2024 Sep;
50(12):108659.
PMID: 39243726
Background: CCA has a poor prognosis. Different anatomical subtypes are characterized by distinct clinical features, surgical options, and prognoses, which can potentially impact survival outcomes following radical resection. In addition...
4.
Ren Y, Li Y, Cao M, Tang Y, Yuan F, Yang G, et al.
Chin J Cancer Res
. 2024 May;
36(2):114-123.
PMID: 38751440
Objective: Unresectable hepatocellular carcinoma (uHCC) continues to pose effective treatment options. The objective of this study was to assess the efficacy and safety of combining low-dose cyclophosphamide with lenvatinib, pembrolizumab...
5.
Song Y, Lian S, Fan H, Ma C, Zheng L, Huang F, et al.
Cancer Lett
. 2024 May;
592:216921.
PMID: 38705565
Cholangiocarcinoma (CCA), an exceptionally aggressive malignancy originating from the epithelium of the bile duct, poses a formidable challenge in cancer research and clinical management. Currently, attention is focused on exploring...
6.
Shi A, Liu Z, Fan Z, Li K, Liu X, Tang Y, et al.
Gut
. 2024 Mar;
73(8):1350-1363.
PMID: 38458750
Objective: The correlation between cholangiocarcinoma (CCA) progression and bile is rarely studied. Here, we aimed to identify differential metabolites in benign and malignant bile ducts and elucidate the generation, function...
7.
Zhang N, Shu L, Liu Z, Shi A, Zhao L, Huang S, et al.
Front Pharmacol
. 2024 Jan;
14:1336685.
PMID: 38269274
Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor that originates from the biliary system. With restricted treatment options at hand, the challenging aspect of early CCA diagnosis leads to a...
8.
Guo Q, Wang J, Cao Z, Tang Y, Feng C, Huang F
Int J Oncol
. 2023 Dec;
64(2).
PMID: 38099379
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the western blotting data shown in Figs. 2B and 3E were strikingly...
9.
Cao M, Ren Y, Li Y, Deng J, Su X, Tang Y, et al.
Int J Biol Sci
. 2023 Aug;
19(12):3678-3693.
PMID: 37564197
Long non-coding RNAs have been reported to play a crucial role in tumor progression in hepatocellular carcinoma (HCC). Lnc-ZEB2-19 has been validated to be deficiently expressed in HCC. However, the...
10.
Zhao L, Liu J, Li K, Zhang C, Chen T, Liu Z, et al.
Hepatology
. 2023 Jul;
79(4):798-812.
PMID: 37505213
Abstract And Aim: Cholangiocarcinoma (CCA) is a highly aggressive and lethal cancer that originates from the biliary epithelium. Systemic treatment options for CCA are currently limited, and the first targeted...